JJ
Johnson & Johnson Portfolio holdings
AUM
$334M
This Quarter Return
+4.85%
1 Year Return
+16.18%
3 Year Return
+88.55%
5 Year Return
–
10 Year Return
–
AUM
$334M
AUM Growth
+$334M
(-2.3%)
Cap. Flow
-$6.99M
Cap. Flow
% of AUM
-2.09%
Top 10 Holdings %
Top 10 Hldgs %
97.27%
Holding
20
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Lyell Immunopharma
LYEL
|
$6.99M |
Sector Composition
| 1 | Healthcare | 99.99% |
| 2 | Technology | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$3.67B
| $136M | 40.83% | 2,449,183 | – | – |
|
2
MeiraGTx Holdings
MGTX
$587M
| $43.9M | 13.14% | 6,641,064 | – | – |
|
|
RAPP
3
Rapport Therapeutics
RAPP
$643M
| $28.6M | 8.55% | 2,498,051 | – | – |
|
4
Legend Biotech
LEGN
$6.41B
| $28.2M | 8.44% | 814,586 | – | – |
|
|
NBTX
5
Nanobiotix
NBTX
$429M
| $25.5M | 7.62% | 5,623,816 | – | – |
|
6
CVRx
CVRX
$205M
| $23.9M | 7.15% | 4,103,430 | – | – |
|
7
Procept Biorobotics
PRCT
$2.23B
| $20.4M | 6.1% | 357,939 | – | – |
|
|
CTNM
8
Contineum Therapeutics
CTNM
$293M
| $8.13M | 2.43% | 1,979,173 | – | – |
|
9
Xencor
XNCR
$580M
| $6.09M | 1.82% | 748,062 | – | – |
|
10
Arrowhead Research
ARWR
$3.05B
| $3.98M | 1.19% | 247,598 | – | – |
|
11
Fate Therapeutics
FATE
$120M
| $3.51M | 1.05% | 3,379,064 | – | – |
|
12
Neumora Therapeutics
NMRA
$280M
| $1.4M | 0.42% | 1,849,445 | – | – |
|
13
Rallybio
RLYB
$22.4M
| $1.21M | 0.36% | 3,636,363 | – | – |
|
14
Vor Biopharma
VOR
$250M
| $1.14M | 0.34% | 1,074,658 | – | – |
|
15
Nano X Imaging
NNOX
$247M
| $831K | 0.25% | 158,852 | – | – |
|
16
Standard BioTools
LAB
$481M
| $371K | 0.11% | 311,967 | – | – |
|
|
17
Lyell Immunopharma
LYEL
$213M
| $368K | 0.11% | 41,165 -782,152 | -95% | -$6.99M |
|
18
Adicet Bio
ACET
$59.9M
| $228K | 0.07% | 364,472 | – | – |
|
19
BiomX
PHGE
$14.3M
| $42.6K | 0.01% | 96,866 | – | – |
|
20
Senseonics Holdings
SENS
$374M
| $27K | 0.01% | 54,621 | – | – |
|